In previous studies, we showed that the administration of 10 μg of the same but recombinantly expressed bsAb CD33-CD3 led to an eradication of over 90% of CD33+ tumor cells in the bone marrow of immunodeficient mice with established AML tumor23. This evidence concerns the gene CD33 and acute myeloid leukemia.